Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>UBS Downgrades GIANT BIOGENE (02367.HK) to Neutral, Slashes TP to $39.5
Recommend 1 Positive 5 Negative 7 |
||||
|
||||
|
UBS released a research report downgrading GIANT BIOGENE (02367.HK) from Buy to Neutral, primarily due to increased uncertainty over short-term revenue and profit outlook. Meanwhile, the broker lowered its 2025-2027 earnings forecasts by 25-41%, and reduced its revenue forecasts for the period by 20-36%. UBS also slashed its target price from $79.5 to $39.5. Market competition intensified now, with other skincare brands or products emerging that offer more attractive pricing while also using recombinant collagen as a core ingredient, the report added. Despite the Company's rapid product innovation, there remains uncertainty about the success of new products next year. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
